Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy

Hypocalcemia is a significant adverse effect of denosumab. We herein report a case of prolonged hypocalcemia in a patient with multiple risk factors for hypocalcemia, including gastrectomy, increased bone turnover, and a poor performance status. Hypocalcemia developed after denosumab treatment for d...

Descripción completa

Detalles Bibliográficos
Autores principales: Iizumi, Sakura, Shimoi, Tatsunori, Nishikawa, Tadaaki, Kitano, Atsuko, Sasada, Shinsuke, Shimomura, Akihiko, Noguchi, Emi, Yunokawa, Mayu, Yonemori, Kan, Shimizu, Chikako, Fujiwara, Yasuhiro, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709630/
https://www.ncbi.nlm.nih.gov/pubmed/28943574
http://dx.doi.org/10.2169/internalmedicine.8908-17
Descripción
Sumario:Hypocalcemia is a significant adverse effect of denosumab. We herein report a case of prolonged hypocalcemia in a patient with multiple risk factors for hypocalcemia, including gastrectomy, increased bone turnover, and a poor performance status. Hypocalcemia developed after denosumab treatment for diffuse bone metastasis of gastric cancer, despite oral supplementation with vitamin D and calcium. To avoid serious prolonged hypocalcemia, a thorough assessment of the bone calcium metabolism is required before initiating denosumab treatment.

Ejemplares similares